Agendia Announces First Patient Enrolled in Prospective LESS Clinical Study, Sponsored by Unicancer, to De-escalate Endocrine Therapy in Women with Early Breast Cancer
The LESS study will evaluate reduced endocrine therapy for HR+/HER2- Read More
Agendia Presents Data from the FLEX Real World Evidence Trial in Seven Posters at ASCO 2022, Showcasing the Power of Its 30,000-Patient Breast Cancer Genome Project
Data show MammaPrint® is the first and most comprehensive FDA-cleared test Read More
Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint
PUBLICATION: ASCO 2021 Authors Joyce O’Shaughnessy1, Virginia G. Kaklamani2, Read More
Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients
Publication: Miami Breast Authors Pat Whitworth, James Read More
The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer
Publication: Miami Breast Authors: Pat Whitworth, Jennifer A. Crozier, Robert Read More
Agendia to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Agendia to Participate in the BTIG MedTech, Digital Health, Life Read More
The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stagebreast cancer
PUBLICATION:SABCS 2020AUTHORS:Laura Lee, Sami Diab, Julie Barone, Jennifer A. Crozier, Read More
5-year outcomes in the NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival
PUBLICATION: SABCS 2020 AUTHORS: Pat Whitworth, James V Pellicane, Read More
The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in older patients
PUBLICATION: SABCS 2020 AUTHORS:Iris Noordhoek, Esther Bastiaannet, Ersan Lujinovic, Laura Read More
Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint
Clinical utility of molecular subtyping and risk of recurrence profiling Read More
